BC is a heterogenous disease [6], and it can be classified into different molecular subtypes [7,8] according to the expression of the (i) human epidermal growth factor receptor 2 (HER2), (ii) estrogen and progesterone receptors (ER and PR, respectively), and/or (iii) the cellular proliferation marker Ki-67a. This evidence concerns the gene ERBB2 and breast cancer.